Combining Vaccines with Conventional Therapies for Cancer.

[1]  J. Allison,et al.  A role for CTLA-4-mediated inhibitory signals in peripheral T cell tolerance? , 2007, Novartis Foundation symposium.

[2]  S. Steinberg,et al.  Five-year overall survival (OS) in non-metastatic androgen-independent prostate cancer (AIPC) patients (pts) treated with nilutamide (N), vaccine (V), and combination therapy , 2007 .

[3]  X. Ran,et al.  Crucial role of SDF-1/CXCR4 interaction in the recruitment of transplanted dermal multipotent cells to sublethally irradiated bone marrow. , 2006, Journal of radiation research.

[4]  W. Urba,et al.  Efficacy of GM-CSF-producing Tumor Vaccine after Docetaxel Chemotherapy in Mice Bearing Established Lewis Lung Carcinoma , 2006, Journal of immunotherapy.

[5]  G. Giaccone,et al.  A dose-escalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular immunotherapy in combination with a fully human anti-CTLA antibody (MDX-010, ipilimumab) in patients with metastatic hormone-refractory prostate cancer (mHRPC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. G. van der Most,et al.  A better way for a cancer cell to die. , 2006, The New England journal of medicine.

[7]  J. Gulley,et al.  A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229). , 2006, Clinical breast cancer.

[8]  S. Steinberg,et al.  A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  G. Bepler,et al.  Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer , 2006, Clinical Cancer Research.

[10]  L. Zitvogel,et al.  Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death , 2005, The Journal of experimental medicine.

[11]  S. Rosenberg,et al.  Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study , 2005, Annals of Surgical Oncology.

[12]  E. Jaffee,et al.  Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. , 2005, Cancer research.

[13]  T. Heng,et al.  Activation of Thymic Regeneration in Mice and Humans following Androgen Blockade , 2005, The Journal of Immunology.

[14]  S. Steinberg,et al.  Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. , 2005, The Journal of urology.

[15]  J. Gribben,et al.  Unexpected Association between Induction of Immunity to the Universal Tumor Antigen CYP1B1 and Response to Next Therapy , 2005, Clinical Cancer Research.

[16]  J. Schlom,et al.  Multiple Costimulatory Modalities Enhance CTL Avidity , 2005, The Journal of Immunology.

[17]  C. N. Coleman,et al.  Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer , 2005, Clinical Cancer Research.

[18]  J. Schlom,et al.  Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. , 2005, Blood.

[19]  C. Drake,et al.  Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. , 2005, Cancer cell.

[20]  J. Schlom,et al.  Sublethal Irradiation of Human Tumor Cells Modulates Phenotype Resulting in Enhanced Killing by Cytotoxic T Lymphocytes , 2004, Cancer Research.

[21]  S. Steinberg,et al.  Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  C. N. Coleman,et al.  External Beam Radiation of Tumors Alters Phenotype of Tumor Cells to Render Them Susceptible to Vaccine-Mediated T-Cell Killing , 2004, Cancer Research.

[23]  C. N. Coleman,et al.  Irradiation of Tumor Cells Up-Regulates Fas and Enhances CTL Lytic Activity and CTL Adoptive Immunotherapy , 2003, The Journal of Immunology.

[24]  Thomas Davis,et al.  Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[25]  E. J. Friedman.  Immune modulation by ionizing radiation and its implications for cancer immunotherapy. , 2002, Current pharmaceutical design.

[26]  Michael S. Kuhns,et al.  CTLA-4: new insights into its biological function and use in tumor immunotherapy , 2002, Nature Immunology.

[27]  R. Crystal,et al.  Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. , 2001, Cancer research.

[28]  E. Jaffee,et al.  Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. , 2001, Cancer research.

[29]  H. Kawai,et al.  Cisplatin Induces Fas Expression in Esophageal Cancer Cell Lines and Enhanced Cytotoxicity in Combination with LAK Cells , 2000, Oncology.

[30]  S. Fulda,et al.  Cytotoxic drugs and the CD95 pathway , 1999, Leukemia.

[31]  J. Schlom,et al.  Comparative studies of a retrovirus versus a poxvirus vector in whole tumor-cell vaccines. , 1999, Cancer research.

[32]  O. Yoshida,et al.  Chemoimmunosensitization of the T24 human bladder cancer line to Fas-mediated cytotoxicity and apoptosis by cisplatin and 5-fluorouracil. , 1999, Oncology reports.

[33]  C. Ioannides,et al.  Increased sensitivity of adriamycin-selected tumor lines to CTL-mediated lysis results in enhanced drug sensitivity. , 1998, Cancer research.

[34]  E. Bonmassar,et al.  Effect of the combined treatment with 5-fluorouracil, gamma-interferon or folinic acid on carcinoembryonic antigen expression in colon cancer cells. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  B. Vojtesek,et al.  Up‐regulation of Fas (CD95) in human p53wild‐type cancer cells treated with ionizing radiation , 1997, International journal of cancer.

[36]  B. Foster,et al.  Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[37]  E. Solary,et al.  Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. , 1997, Journal of the National Cancer Institute.

[38]  I. Melero,et al.  Costimulation, tolerance and ignorance of cytolytic T lymphocytes in immune responses to tumor antigens. , 1997, Life sciences.

[39]  R. Schwartz,et al.  Models of T Cell Anergy: Is There a Common Molecular Mechanism? , 1996 .

[40]  J. Allison,et al.  Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.

[41]  J. Allison,et al.  Manipulation of costimulatory signals to enhance antitumor T-cell responses. , 1995, Current opinion in immunology.

[42]  G. Blair,et al.  Mechanism of synergy of levamisole and fluorouracil: induction of human leukocyte antigen class I in a colorectal cancer cell line. , 1995, Journal of the National Cancer Institute.

[43]  S. Kumar,et al.  Irradiation induced expression of CD31, ICAM-1 and VCAM-1 in human microvascular endothelial cells. , 2000, Anticancer research.

[44]  S. Piantadosi,et al.  Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines. , 1998, International journal of oncology.

[45]  R. Schwartz,et al.  Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. , 1989, Annual review of immunology.